Pr David Devos

Pr David Devos

 

Fonctions

Neurologue spécialiste des mouvements anormaux, professeur de pharmacologie clinique et fondamentale

Lieu d’exercice

Université de Lille, CHU de Lille, Inserm UMR-1172 Lille Neuroscience & Cognition research centre

Expertises et thématiques de recherche

Développement de nouvelles stratégies thérapeutiques (symptomatiques et de « disease modification ») et de biomarqueurs dans la maladie de Parkinson et la sclérose latérale amyotrophique à l’aide d’études translationelles, d’études cliniques et d’essais thérapeutiques de phase I et II

Nombre de publications

 > 200 publications

Nombre de projets nationaux et internationaux

  • 30 études dont 14 essais multicentriques et 14 en tant que coordinateur (10 en cours), 4 projets financés par la Commission européenne (H2020) dont 2 en neurosciences (fer, mort cellulaire ferroptotique), 1 large essai clinique européen FAIRPARK-2 http://www.fairpark2.eu/people/david-devos et 1 sur le diagnostic sur Covid-19.
  • 6 brevets conduisant à 3 transferts industriels via cofondation de 3 Start up (InBrain Pharma pour la perfusion cérébrale, InVenis Biotherapies pour les biothérapies à base de plaquettes et CorDial-IT pour les outils de diagnostic). 

Quelques projets phares

  • PREDISTIM: Multicentric study of the predictive factors of the therapeutic response to subthalamic stimulation on the long-term quality of life and study of the pharmacogenetic factors of the L-dopa treatment response in Parkinson’s disease Protocol ID: 2013-A00193-42; ClinicalTrials.gov: NCT02360683
  • PULSE: Multicentric study of the Pronostic valUe of biomarkers in amyotrophic Lateral Sclerosis & Endophenotypic study Protocol ID: 2013-A00969-36; ClinicalTrials.gov: NCT02360891
  • FAIR-PARK-II: European multicentric study of Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease: a multicentre, parallel-group, placebo-controlled, randomized clinical trial of deferiprone; ClinicalTrials.gov Identifier: NCT02655315 http://www.fairpark2.eu/
  • FAIR-ALS-II Conservative Iron Chelation by Deferiprone as a Disease-modifying Strategy for Amyotrophic Lateral Sclerosis using a Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial on 240 patients. Protocol ID: 2017-003763-35; ClinicalTrials.gov: NCT03293069
  • PACTE-I Potentiation of cognitive functions in healthy elderly by association of methylphenidate and cognitive training: Proof of concept study in order to develop a synergic symptomatic treatment of cognitive disorders before dementia. Protocol ID: 2015_81; ClinicalTrials.gov: NCT03280251
  • PRION-IRON: European funds from (Network of Centres of Excellence in Neurodegeneration (CoEN) (PRION like propagation of synucleinopathy associated with ferroptosis, the IRON dependent cell death): to develop new therapeutic strategies against ferroptosis
  • PARKINSUN: Evaluation of a New Communication Aid Tool to Favor Global Patient Centered Care. Protocol ID: 2018_74 ; ClinicalTrials.gov: NCT04179695
  • DIVE: Evaluation of the safety and efficacy of continuous dopaminergic stimulation by intracerebroventricular administration of anaerobic dopamine conserved in Parkinson's disease at the motor fluctuation stage. Trial Registration: Protocol ID: 2018_49; French Ethical Committee; 2020-000155-12; ClinicalTrials.gov ID: NCT04332276, academic patents with industrial transfer with a start-up creation: InBrain Pharma https://www.inbrainpharma.com/  
  • GIFT project (biothérapie: Growth factor preparations from platelets & neuroprotective strategies) 3 patents and one industrial transfer in progress with start-up creation InVenis biotherapies.
  • CorDial-1 patent (methods for detecting a target in a sample using mutated nanobodies) with one industrial transfer in progress with start-up creation CorDial-IT

 

Français